natgillin/translations-raw huggingface dataset:
Common: headache (4.4%), lethargy (1.1%), dizziness (2.6%) Rare: paraesthesia* 
Bolezni živčevja pogosti: glavobol (4,4 %), letargičnost (1,1 %), omotica (2,6 %) redki: parestezija*
Investigations Common: decreased blood cortisol (2.2%) 
Preiskave pogosti: zmanjšana raven kortizola v krvi (2,2 %) Opis izbranih neželenih učinkov
Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, somatropin and agonists, ATC code: H01AC01 
Farmakoterapevtska skupina: hipofizni in hipotalamični hormoni in sorodne učinkovine, hormoni prednjega režnja hipofize in sorodne učinkovine, oznaka ATC: H01AC01
4 vials of 20 mg powder 
4 viale z 20 mg praška
Fatty tissue under the skin can shrink at the site of injection on repeated administration at the same site. 
Maščobo tkivo pod kožo se lahko na mestu injiciranja skrči, če si zdravilo pogosto injicirate v isto mesto.
Patients receiving concomitant glucocorticoid therapy should have their dose carefully adjusted. 
Pri bolnikih, ki se sočasno zdravijo z glukokortikoidi, je treba odmerek skrbno prilagoditi.
Paediatric population (below 2 years of age) Somatropin Biopartners should not be used in infants below the age of 2 years. 
Zdravila Somatropin Biopartners ne uporabljajte pri dojenčkih, starih manj kot 2 leti.
4 vials of 10 mg powder 
4 viale z 10 mg praška
Paediatric patients with endocrine disorders, including GHD, may develop slipped capital femoral epiphyses more frequently. 
Pri pediatričnih bolnikih z motnjami pri delovanju žlez z notranjim izločanjem, tudi z GHD, lahko pogosteje kot pri splošni populaciji zdrsne epifiza stegnenične glavice.
Psychiatric disorders Very rare: insomnia* 
Psihiatrične motnje zelo redki: nespečnost*
The powder is white to almost white, the solvent is a clear liquid. 
Prašek je bel do belkast, vehikel pa je bistra tekočina.
Excessive glucocorticoid therapy can inhibit the actions of hGH. 
Čezmerno zdravljenje z glukokortikoidi lahko zavira učinek hGH.
General disorders and administration site conditions Very common: Oedema peripheral, oedema (local and generalised)* Common: Fatigue, pain, asthenia, face oedema, local swelling, oedema, thirst, malaise, chest pain, increased weight, injection site pain 
Splošne težave in spremembe na mestu aplikacije zelo pogosti: periferni edem, edem (lokalni in generaliziran)* pogosti: utrujenost, bolečina, astenija, obrazni edem, lokalna oteklina, edem, žeja, splošno slabo počutje, bolečine v prsnem košu, povečanje telesne mase, bolečina na mestu injiciranja
Vigorously swirl the vial without touching the rubber top with your fingers until the content is completely mixed. 
Močno vrtite vialo, dokler ni vsebina povsem premešana, pri tem pa se ne dotikajte gumijastega vrha.
Musculoskeletal and connective tissue disorders Common: arthralgia (1.1%), pain in extremities (5.1%) 
Bolezni mišično-skeletnega sistema in vezivnega tkiva pogosti: artralgija (1,1 %), bolečine v okončinah (5,1 %)
The following adverse reactions have been observed under treatment with Somatropin Biopartners in a 12-month controlled comparative clinical study in 178 treatment naïve children with growth failure due to insufficient secretion of endogenous growth hormone and in a dose finding study. 
Naslednje neželene učinke so opazili pri zdravljenju z zdravilom Somatropin Biopartners v 12-mesečni kontrolirani primerjalni klinični študiji s 178 otroci, ki se predhodno še niso zdravili, z zaostankom v rasti zaradi nezadostnega izločanja normalnega endogenega rastnega hormona, in v študiji za določanje odmerka.
Somatropin Biopartners is not recommended in women of childbearing potential not using contraception. 
Zdravila Somatropin Biopartners ne uporabljajte pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
Female (on oral oestrogen) 
Ženske (ki dobivajo peroralni estrogen)
Cardiac disorders Common: Tachycardia, heart rate abnormal/irregular 
Srčne bolezni pogosti: tahikardija, nenormalen/nepravilen srčni utrip
Inject the entire contents of the syringe into the vial of powder, holding the syringe against the vial wall. 
Celotno vsebino injekcijske brizge injicirajte v vialo s praškom, pri tem pa držite iglo injekcijske brizge ob steno viale.
Following repeated weekly subcutaneous administration of a mean dose of 0.5 mg/kg prolonged release somatropin to prepubertal children with GHD the Cmax and tmax of plasma hGH were about 60.7 ng/mL and 12.0 h respectively. 
Po ponavljajočem se tedenskem subkutanem dajanju povprečnega odmerka 0,5 mg/kg somatropina s podaljšanim sproščanjem otrokom pred puberteto s pomanjkanjem rastnega hormona, je bil Cmax plazemskega hGH približno 60,7 ng/ml in tmax 12,0 ur.
The syringe should be filled with the correct volume of the solvent for injection as listed above and the syringe needle withdrawn from the vial subsequently. 
Injekcijsko brizgo napolnite s pravilno količino vehikla za injekcijo, kot je navedeno zgoraj, nato pa iglo injekcijske brizge izvlecite iz viale.
- 0.7 mL in a 1 mL graduated syringe for Somatropin Biopartners 10 mg - 1.2 mL in a 2 mL graduated syringe for Somatropin Biopartners 20 mg 
- 0,7 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 10 mg - 1,2 ml v 2 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 20 mg
- if you are allergic to somatropin or any of the other ingredients of this medicine (listed in section 6); - if you have cancer; Tell your doctor if you have an active tumour (cancer). 
- če ste alergični na somatropin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Put an adhesive plaster on the injection site. 
Na mesto injiciranja zalepite obliž.
Leukaemia has been reported in a small number of GHD patients, some of whom have been treated with somatropin. 
Pri majhnem številu bolnikov z GHD, zdravljenih s somatropinom, so poročali o levkemiji.
Use immediately, as the suspension may settle if left standing. 
Zdravilo takoj uporabite, saj se lahko suspenzija v nasprotnem primeru usede.
Eye disorders Common: Conjunctivitis, visual acuity reduced 
Očesne bolezni pogosti: konjunktivitis, zmanjšana ostrina vida
- 0.4 mL in a 1 mL graduated syringe for Somatropin Biopartners 2 mg - 0.6 mL in a 1 mL graduated syringe for Somatropin Biopartners 4 mg - 0.9 mL in a 1 mL graduated syringe for Somatropin Biopartners 7 mg 
- 0,4 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 2 mg - 0,6 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 4 mg - 0,9 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 7 mg
If you use more Somatropin Biopartners than you should 
Če ste uporabili večji odmerek zdravila Somatropin Biopartners, kot bi smeli
Other medicines and Somatropin Biopartners 
Druga zdravila in zdravilo Somatropin Biopartners
Growth hormone increases the extrathyroidal conversion of T4 to T3 which may result in a reduction in serum T4 and an increase in serum T3 concentrations. 
Posledica tega je zmanjšanje serumske vrednosti T4 in zvečanje koncentracije T3.
The results showed weekly administered Somatropin Biopartners to be non inferior to daily administered recombinant hGH with respect to the primary endpoint of height velocity after 12 months. 
Rezultati so pokazali, da tedensko dajanje zdravila ni bilo slabše kot dnevno dajanje rekombinantnega hGH glede primarnega cilja študije, hitrosti rasti po 12 mesecih.
Somatropin Biopartners 10 mg is sufficient for use in children up to 20 kg bodyweight. 
Zdravilo Somatropin Biopartners 10 mg zadošča za uporabo pri otrocih s telesno maso do 20 kg.
In children, Somatropin Biopartners should be administered subcutaneously at a concentration of 20 mg/mL. 
Pri otrocih se zdravilo Somatropin Biopartners daje subkutano v koncentraciji 20 mg/ml.
Withdraw the syringe needle from the vial. 
Iglo injekcijske brizge izvlecite iz viale.
Remove the needle guard and fill the syringe with a volume of air equal to the required volume of the solvent for injection, making it easier to withdraw the solvent: 
Z injekcijske brizge odstranite varovalo in jo napolnite z volumnom zraka, ki je enak količini potrebnega vehikla za injiciranje, da boste lažje izvlekli vehikel:
Gently tap the syringe to remove small air bubbles. 
Po injekcijski brizgi nežno potolcite, da odstranite majhne zračne mehurčke.
Somatropin Biopartners 20 mg is sufficient for use in children up to 40 kg bodyweight. 
Zdravilo Somatropin Biopartners 20 mg zadošča za uporabo pri otrocih s telesno maso do 40 kg.
Insert the needle through the centre of the rubber stopper of the solvent vial and inject all of the air into the vial. 
Iglo vstavite skozi sredino gumijastega zamaška viale z vehiklom ter ves zrak injicirajte v vialo.
IGF-I SDS in the range of -1 to +1 and more than 1 SDS increase from Baseline Maintain 
SDS IGF-I v razponu -1 do +1 in več kot 1 SDS povečanje od izhodišča brez
Common: Paraesthesia, hypoaesthesia, carpal tunnel syndrome, dizziness, somnolence Rare: Benign intracranial hypertension* 
Bolezni živčevja zelo pogosti: glavobol pogosti: parestezija, hipestezija, sindrom karpalnega kanala, omotica, zaspanost redki: benigna intrakranialna hipertenzija*
Turn the vial upside down, with the syringe in and place the tip of the needle in the suspension as shown in figure 9. 
Vialo obrnite navzdol z injekcijsko brizgo v njej in konico igle potisnite v suspenzijo, kot prikazuje slika 9.
Common: Back pain, pain in extremities, arthralgia, shoulder pain, musculoskeletal stiffness, bone pain, muscular weakness, sensation of heaviness, tendonitis, joint swelling, arthritis, musculosceletal pain, myalgia* 
Bolezni mišično-skeletnega sistema in vezivnega tkiva pogosti: bolečine v hrbtu, bolečine v okončinah, artralgija, bolečine v ramenih, mišično-skeletna togost, bolečine v kosteh, mišična šibkost, občutek teže, tendonitis, oteklost sklepov, artritis, mišičnoskeletna bolečina, mialgija*
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte s svojim zdravnikom, farmacevtom ali medicinsko sestro.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Solvent for Somatropin Biopartners 
IME ZDRAVILA IN POT(I) UPORABE vehikel za zdravilo Somatropin Biopartners
Reproductive system and breast disorders Very rare: gynaecomastia* 
Motnje reprodukcije in dojk zelo redki: ginekomastija*
Important information about some of the ingredients of Somatropin Biopartners 
Pomembne informacije o nekaterih sestavinah zdravila Somatropin Biopartners
QUALITATIVE AND QUANTITATIVE COMPOSITION One vial delivers 20 mg of somatropin* (corresponding to 60 IU) After reconstitution, 1 mL of suspension contains 20 mg somatropin (20 mg/mL). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena viala dostavi 20 mg somatropina* (kar ustreza 60 i.e.) Po rekonstituciji 1 ml suspenzije vsebuje 20 mg somatropina (20 mg/ml).
The following adverse reactions have been observed under treatment with Somatropin Biopartners in a 6-month controlled clinical study with 151 adult patients with GHD of adult or childhood-onset and in a 6-month extension study. 
Naslednje neželene učinke so opazili pri zdravljenju z zdravilom Somatropin Biopartners v 6-mesečni kontrolirani klinični študiji s 151 odraslimi bolniki s pomanjkanjem rastnega hormona z začetkom v odrasli dobi ali v otroštvu, in v 6-mesečnem podaljšku študije.
Common: Adrenal insufficiency, decreased free thyroxine, decreased free tri-iodothyronine, increased blood TSH, hypothyroidism* 
Bolezni endokrinega sistema pogosti: adrenalna insuficienca, zmanjšanje vrednosti prostega tiroksina, zmanjšanje vrednosti prostega trijodtironina, povečanje vrednosti TSH v krvi, hipotiroidizem*
After preparation, the product must be used immediately. 
Pripravljeno zdravilo je treba uporabiti takoj.
Tumours must be inactive and cancer therapy complete before you can start your treatment with growth hormone. 
Tumorji morajo biti neaktivni, preden začnete zdravljenje z rastnim hormonom, pa morate zaključiti zdravljenje tumorja.
Do not use Somatropin Biopartners 
Ne uporabljajte zdravila Somatropin Biopartners
The amino acid sequence of the active substance is identical to that of hGH of pituitary origin. 
Aminokislinsko zaporedje zdravilne učinkovine je identično aminokislinskemu zaporedju hGH hipofiznega izvora.
Investigations Common: Increased blood phosphorus, increased or decreased IGF 
Preiskave pogosti: povečana raven fosforja v krvi, povečana ali zmanjšana raven insulinu podobnega rastnega dejavnika
The syringe should be filled with a volume of air equal to the required volume of the solvent for injection and the air injected into the solvent vial to make it easier to withdraw the solvent. 
Injekcijsko brizgo napolnite z volumnom zraka, ki je enak količini potrebnega vehikla za injiciranje, in zrak injicirajte v vialo z vehiklom za lažji izvlek vehikla.
Powder and solvent for prolonged-release suspension for injection 20 mg powder in a vial and 1.5 mL solvent in a vial 1 vial of 20 mg powder 
Vehikel: srednjeverižni trigliceridi prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem 20 mg prašek v viali in 1,5 ml vehikla v viali 1 viala z 20 mg praška
Use a 1 mL or 2 mL graduated syringe with a 19G or wider needle for withdrawing the solvent from its vial. 
Uporabite 1 ml ali 2 ml graduirano injekcijsko brizgo z iglo velikosti 19 G ali večjo, da izvlečete vehikel iz viale.
Hold the syringe upright. 
Injekcijsko brizgo držite navpik.
The other ingredients are sodium hyaluronate, egg phospholipids, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. 
Druge sestavine zdravila so natrijev hialuronat, jajčni fosfolipidi, brezvodni natrijev dihidrogenfosfat in brezvodni dinatrijev fosfat.
Common, may affect up to 1 in 10 people - tiredness or weight gain due to underactive thyroid gland - reduced function of the adrenal gland (which may show as tiredness) - mild blood sugar increase - headache, lethargy (lack of energy), dizziness - vomiting, stomach ache - discoloration of the skin - pain in joints, arms or legs - pain, discoloration, swelling, hardening, reddening or feeling of warmth at the injection site - tissue swelling - fever - changes in blood levels of certain hormones 
Pogosti; pojavijo se lahko pri največ 1 od 10 bolnikov - utrujenost ali pridobivanje telesne mase zaradi premalo aktivne ščitnice - zmanjšano delovanje nadledvične žleze (kar se kaže kot utrujenost) - blago povečanje krvnega sladkorja - glavobol, letargičnost (pomanjkanje energije), omotica - bruhanje, bolečine v trebuhu - obarvanje kože - bolečine v sklepih, rokah ali nogah - bolečina, obarvanje, oteklina, otrdlina, rdečina ali občutek vročine na mestu injiciranja - oteklina tkiva - povečana telesna temperatura - spremenjeni ravni nekaterih hormonov v krvi
Somatropin Biopartners is indicated in children and adolescents aged 2 to 18 years for long-term treatment of growth failure due to insufficient secretion of endogenous growth hormone. 
Zdravilo Somatropin Biopartners je indicirano pri otrocih in mladostnikih, starih od 2 do 18 let, z zaostankom v rasti zaradi nezadostnega izločanja normalnega endogenega rastnega hormona.
Turn the vial upside down, with the syringe inside and place the tip of the needle in the solvent as seen in figure 5. 
Vialo obrnite navzdol z injekcijsko brizgo v njej in konico igle potisnite v vehikel, kot prikazuje slika 5.
Neoplasms benign, malignant and unspecified (including cysts and polyps) Common: Neoplasm progression (1 case of neoplasm progression in a female patient with a history of neurofibromatosis and radiation treatment), acrochordon, craniopharyngioma 
pogosti: napredovanje novotvorbe (1 primer napredovanja novotvorbe pri bolnici z anamnezo nevrofibromatoze in zdravljenja z obsevanjem), akrohordon, kraniofaringiom
Hypothyroidism may develop in patients with central subclinical hypothyroidism after initiating therapy with growth hormone. 
Pri bolnikih s centralnim subkliničnim hipotiroidizmom se lahko pri uvedbi zdravljenja z rastnim hormonom pojavi hipotiroidizem.
IGF-I SDS in the range of -1 to +1 and less than 1SDS increase from Baseline 
SDS IGF-I v razponu -1 do +1 in manj kot 1 SDS povečanje od izhodišča povečanje
Holding the needle against the inside vial wall, the entire contents of the syringe should be injected into the powder vial. 
Iglo držite na notranjo steno viale in v vialo s praškom injicirajte celotno vsebino injekcijske brizge.
There is no antidote for somatropin overdose. 
Za preveliki odmerek somatropina ni znanega antidota.
Animal studies are insufficient with respect to reproductive toxicity (see section 
Ni dovolj študij na živalih o vplivu zdravila na sposobnost razmnoževanja (glejte poglavje 5.3).
If you stop using Somatropin Biopartners 
Če ste prenehali uporabljati zdravilo Somatropin Biopartners
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Cases of malignant and benign tumour recurrences, de-novo and secondary tumours have been reported in temporal relationship with somatropin therapy. 
V časovnem razmerju z zdravljenjem s somatropinom so poročali o primerih ponovnih pojavov malignih in benignih tumorjev, na novo nastalih tumorjev in sekundarnih tumorjev.
The plunger should be pushed up gently, until all bubbles are removed from the syringe and needle. 
Bat nežno potiskajte, dokler ne odstranite vseh mehurčkov iz injekcijske brizge in igle.
The 20-mg vial contains an overfill of somatropin powder to allow the withdrawal of up to 20 mg (1 mL suspension) of somatropin when reconstituted. 
20-mg viala vsebuje presežek praška somatropina, kar omogoči odvzem do 20 mg (1 ml suspenzije) rekonstituiranega somatropina.
Somatropin Biopartners 2 mg powder and solvent for prolonged-release suspension for injection Somatropin Biopartners 4 mg powder and solvent for prolonged-release suspension for injection Somatropin Biopartners 7 mg powder and solvent for prolonged-release suspension for injection 
Somatropin Biopartners 2 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem Somatropin Biopartners 4 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem Somatropin Biopartners 7 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem za odrasle
Somatropin Biopartners should be administered subcutaneously at a concentration of 10 mg/mL. 
Zdravilo Somatropin Biopartners se daje subkutano v koncentraciji 10 mg/ml.
Common, may affect up to 1 in 10 people - virus infection known as Herpes simplex - skin tag (a form of harmless skin growth) - tiredness - weakness, feeling unwell - face swelling - thirst - pain, chest pain, pain at the injection site - pain in the back, arms, legs, shoulders, bones, joints - sleeplessness - decreased sensation, numbness and tingling in fingers and palm of the hand due to squeezed nerve at wrist (carpal tunnel syndrome) - dizziness, sleepiness - muscular or bone stiffness, weakness of the muscles, muscle pain, feeling of heaviness - inflammation of the tendons, joint swelling, joint inflammation - reddening of the eyes, reduced vision, vertigo (a feeling of dizziness or spinning) - increased or irregular heart rate - high blood pressure - nosebleed - nausea - increased level of bilirubin, a substance produced by the liver - inflammation of the gall bladder - acne, increased sweating, skin rash - allergic skin reactions such as redness, irritation, itching - blood in the urine - nipple pain - reduced function of the adrenal gland (which could show as tiredness) - reduced function of the thyroid gland - increased fat levels in the blood - weight gain - development of substances (antibodies) in the blood that bind to growth hormone - changes in blood test results such as a change in the number of white blood cells or increased levels of insulin, sugar, sodium or certain fatty substances in the blood - changes in liver test results - a type of benign brain tumour called craniopharyngioma 
- visok krvni tlak - krvavitev iz nosu - slabost - zvišana raven bilirubina, snovi, ki nastaja v jetrih - vnetje žolčnika - akne, povečano potenje, kožni izpuščaj - alergijske kožne reakcije, kot so rdečina, draženje, srbenje - kri v urinu - boleče prsne bradavice - zmanjšano delovanje nadledvične žleze (kar se lahko kaže v obliki utrujenosti) - zmanjšano delovanje žleze ščitnice - zvišane ravni maščob v krvi - pridobivanje telesne mase - razvoj snovi (protiteles) v krvi, ki vežejo rastni hormon - spremenjeni rezultati krvnih preiskav, kot so spremenjeno število belih krvnih celic ali zvišane ravni insulina, sladkorja, natrija ali nekaterih maščobnih snovi v krvi - spremenjeni rezultati jetrnih preiskav - vrsta benignega možganskega tumorja, imenovanega kraniofaringiom
What Somatropin Biopartners looks like and contents of the pack 
Izgled zdravila Somatropin Biopartners in vsebina pakiranja
To avoid this, always change the injection site between injections. 
Da to preprečite, vsakič izberite drugo mesto injiciranja.
Solvent: medium chain triglycerides. 
Vehikel: srednjevreižni trigliceridi
Common: Decreased or increased white blood cell count, increased glycosylated haemoglobin, decreased haemoglobin 
Bolezni krvi in limfatičnega sistema pogosti: zmanjšano ali povečano število belih krvnih celic, povečana raven glikoziliranega hemoglobina, zmanjšana raven hemoglobina
Solvent: Medium chain triglycerides. 
Vehikel: srednjeverižni trigliceridi
Your doctor will stop your treatment with this medicine if there is evidence of cancerous growth; - if you are ill due to a serious heart or stomach operation; 
Vaš zdravnik bo zdravljenje s tem zdravilom ustavil, če bodo obstajali dokazi rakave rasti.
Psychiatric disorders Common: Insomnia 
Psihiatrične motnje pogosti: nespečnost
If you forget to use Somatropin Biopartners 
Če ste pozabili vzeti zdravilo Somatropin Biopartners
Any child with the onset of a limp during growth hormone therapy should be evaluated. 
Vsakega otroka, pri katerem se med zdravljenjem s somatropinom pojavi šepanje, je treba klinično pregledati.
Hepatobiliary disorders Common: Hyperbilirubinaemia, cholecystitis, liver test abnormal 
Bolezni jeter, žolčnika in žolčevodov pogosti: hiperbilirubinemija, holecistitis, nenormalni rezultati jetrnih testov
Repeated adjustments in dose may be required, dependent on patients' IGF-I response. 
Glede na bolnikov odziv IGF-I bo morda treba odmerek ponovno prilagoditi.
Withdrawing the suspension 
Izvlek suspenzije
Use a 1 mL graduated syringe with a 19G or wider needle for withdrawing the solvent from its vial. 
Uporabite 1 ml graduirano injekcijsko brizgo z iglo velikosti 19 G ali večjo, da izvlečete vehikel iz viale.
For other doses vials with 4 or 7 mg somatropin are available. 
Za druge odmerke so na voljo viale s 4 ali 7 mg somatropina.
Common: Impaired fasting glucose, hyperlipidaemia, increased blood insulin, increased blood cholesterol, decreased blood sodium, increased blood triglycerides, increased blood glucose, increased or decreased HDL, increased LDL 
Presnovne in prehranske motnje zelo pogosti: blaga hiperglikemija* pogosti: vpliv na glukozo na tešče, hiperlipidemija, povečanje ravni insulina v krvi, povečanje ravni holesterola v krvi, zmanjšanje ravni natrija v krvi, povečanje ravni trigliceridov v krvi, povečanje ravni glukoze v krvi, povečanje ali zmanjšanje ravni HDL, povečanje ravni LDL neznana: odpornost na insulin*
Ask your doctor for advice before stopping treatment. 
Preden prenehate z zdravljenjem, se posvetujte s svojim zdravnikom.
For other doses vials with 2 or 7 mg somatropin are available. 
Za druge odmerke so na voljo viale z 2 ali 7 mg somatropina.
Information about self-injection of Somatropin Biopartners 
Informacije o samoinjiciranju zdravila Somatropin Biopartners
Non-clinical data revealed no specific hazard for humans based on conventional studies of repeated dose toxicity and genotoxicity. 
Predklinični podatki na osnovi običajnih študij toksičnosti pri ponavljajočih odmerkih in genotoksičnosti ne kažejo posebnega tveganja za človeka.
For other doses vials with 2 or 4 mg somatropin are available. 
Za druge odmerke so na voljo viale z 2 ali 4 mg somatropina.
Male 
Moški